You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
McKinsey
Express Scripts
Merck
Medtronic

Last Updated: March 7, 2021

DrugPatentWatch Database Preview

CLEOCIN Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Cleocin, and when can generic versions of Cleocin launch?

Cleocin is a drug marketed by Pharmacia And Upjohn and is included in fourteen NDAs. There is one patent protecting this drug.

This drug has twenty-four patent family members in twenty-two countries.

The generic ingredient in CLEOCIN is clindamycin palmitate hydrochloride. There are fifty-five drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the clindamycin palmitate hydrochloride profile page.

Summary for CLEOCIN
International Patents:24
US Patents:1
Applicants:1
NDAs:14
Suppliers / Packagers: 2
Bulk Api Vendors: 102
Clinical Trials: 9
Patent Applications: 1,215
Formulation / Manufacturing:see details
Drug Prices: Drug price information for CLEOCIN
What excipients (inactive ingredients) are in CLEOCIN?CLEOCIN excipients list
DailyMed Link:CLEOCIN at DailyMed
Drug patent expirations by year for CLEOCIN
Drug Prices for CLEOCIN

See drug prices for CLEOCIN

Drug Sales Revenue Trends for CLEOCIN

See drug sales revenues for CLEOCIN

Recent Clinical Trials for CLEOCIN

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Roswell Park Cancer InstitutePhase 4
National Cancer Institute (NCI)Phase 4
Tianjin Medical University Cancer Institute and HospitalN/A

See all CLEOCIN clinical trials

Pharmacology for CLEOCIN

US Patents and Regulatory Information for CLEOCIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pharmacia And Upjohn CLEOCIN clindamycin hydrochloride CAPSULE;ORAL 061809-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
Pharmacia And Upjohn CLEOCIN T clindamycin phosphate GEL;TOPICAL 050615-001 Jan 7, 1987 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Pharmacia And Upjohn CLEOCIN clindamycin phosphate SUPPOSITORY;VAGINAL 050767-001 Aug 13, 1999 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Pharmacia And Upjohn CLEOCIN clindamycin phosphate CREAM;VAGINAL 050680-002 Mar 2, 1998 AB RX Yes Yes   Start Trial   Start Trial   Start Trial
Pharmacia And Upjohn CLEOCIN PHOSPHATE clindamycin phosphate INJECTABLE;INJECTION 061839-001 Approved Prior to Jan 1, 1982 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for CLEOCIN

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1304992 2013C/060 Belgium   Start Trial PRODUCT NAME: CLINDAMYCINE (ALS CLINDAMYCINE FOSFAAT) EN TRETINOINE; AUTHORISATION NUMBER AND DATE: BE437507 20130506
1304992 CR 2013 00053 Denmark   Start Trial PRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322
1304992 SPC/GB13/061 United Kingdom   Start Trial PRODUCT NAME: CLINDAMYCIN PHOSPHATE IN COMBINATION WITH TRETINOIN.; REGISTERED: IE PA1332/043/001 20130322; UK PL15142/0249 20130624
1304992 C300617 Netherlands   Start Trial PRODUCT NAME: COMBINATIE VAN CLINDAMYCINE, DESGEWENST IN DE VORM VAN CLINDAMYCINEFOSFAAT EN TRETINOINE; NAT. REGISTRATION NO/DATE: RVG 109745 20130626; FIRST REGISTRATION: PA1332/043/001 20130322
1304992 2013/044 Ireland   Start Trial PRODUCT NAME: CLINDAMYCIN AND TRETINOIN; REGISTRATION NO/DATE: PA1332/043/001 20130322
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Dow
Baxter
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.